Latest News
Press Releases
- 10.26.09 - Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
- 10.21.09 - AGA Institute and Horizon Therapeutics Expand CONNECT to Protect Program to Educate Consumers on NSAID Risk
- 06.29.09 - Horizon Therapeutics Names Dr. Jeffery W. Sherman Executive Vice President and Chief Medical Officer
- 06.01.09 - Horizon Therapeutics' HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients with Mild-to-Moderate Pain
- 06.01.09 - AGA Institute and Horizon Therapeutics Launch "Connect to Protect" Program to Educate Physicians and Consumers on Risks Associated with NSAID Use
- 03.23.09 - Horizon Therapeutics Selected to Present at InsideVenture's Debut Investor Conference March 25-26, Santa Barbara, California
- 01.06.09 - Horizon Therapeutics Announces Senior Management Appointments
- 12.02.08 - Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
- 10.09.08 - Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
- 10.01.08 - Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
- 09.19.08 - Horizon Therapeutics to Present at UBS Global Life Sciences Conference
- 07.31.08 - Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
- 07.24.08 - Horizon Therapeutics Names Timothy P. Walbert as President and CEO
- 02.11.08 - Horizon Therapeutics Completes Enrollment in Phase 3 for Trials for Lead Product Candidate HZT-501
- 10.08.07 - Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
- 07.23.07 - Horizon Therapeutics Completes $30 Million Equity Financing to Advance Pipeline of "GI-friendly" NSAIDS for Mild-to-Moderate Pain
- 03.27.07 - Horizon Therapeutics Begins Patient Enrollment in Phase 3 Trials For "GI-Friendly" NSAID
- 01.08.07 - Horizon Therapeutics announces Special Protocol Assessment with FDA for Phase 3 trial program
- 01.04.07 - Horizon Therapeutics completes $21 million in equity financing to advance pipeline of "GI-friendly" NSAIDs for mild-to-moderate pain